Peyronie's Disease and Erectile Dysfunction: The Scar Tissue Connection Explained

Yes — in a study of 534 men being screened for prostate cancer, Peyronie's disease was significantly associated with lower SHIM scores, a measure of erectile function [1]. Mechanisms include: venous leak from tunica albuginea damage, mechanical deformity preventing penetration, pain-conditioned sexual avoidance, and psychological distress from penile deformity. PD and ED share management: PDE5 inhibitors address both conditions, and penile implant insertion simultaneously corrects curvature and treats ED.

No permanent cure — but effective management exists. FDA-approved collagenase (Xiaflex) injections reduce curvature by ~35% in the acute phase. Traction devices prevent progression and shortening. Surgical options in the stable phase (Nesbit plication, grafting, penile implant) provide definitive correction. Penile implant with manual modeling is the gold standard when both significant curvature and severe ED are present.

Yes — immediately if you notice new penile curvature, pain with erection, or a palpable lump under the skin. Acute-phase treatment (within first 12 months) offers the best opportunity to slow progression. A urologist specializing in sexual medicine can stage the disease, confirm whether you're in active or stable phase, and select appropriate treatment (injections, traction, or surgery).

Not always — it depends on which mechanism is driving the ED. If erectile difficulty is purely mechanical (rigidity is fine but curvature prevents penetration), correcting the curvature alone often resolves the functional problem. If there's a genuine venous leak component from tunica damage, curvature correction alone may not fully restore erectile rigidity, and a PDE5 inhibitor or additional ED-specific treatment may still be needed. This is why a thorough evaluation distinguishing the mechanical, vascular, and psychological contributors matters — treating the visible curvature without addressing a co-existing vascular or psychological driver of ED can leave a man with straighter anatomy but persistent erectile difficulty.

There's supporting evidence for both roles simultaneously, which is part of why daily low-dose tadalafil is sometimes specifically recommended in Peyronie's disease management rather than just as an ED treatment. Beyond its standard erectile-function benefit, daily tadalafil has been studied for a potential role in modestly slowing Peyronie's disease progression, plausibly through improved penile tissue oxygenation, though this effect is less robustly established than its ED benefit. For men with both conditions, this dual-purpose profile makes it a reasonable first-line medical option to discuss with a urologist before considering more invasive interventions.

Yes, in some cases — vacuum erection devices can help maintain erectile tissue health and, in certain protocols, are used alongside traction therapy or after collagenase injections to help mechanically stretch and remodel the plaque area during the healing process. They're generally considered an adjunct rather than a primary standalone treatment for combined Peyronie's-and-ED cases, and their appropriate use is best determined with a urologist familiar with the specific stage and severity of the curvature and erectile issue.

This is a recognized and fairly common pattern, not a rare or exaggerated concern. The combination of visible physical change, uncertainty about what a partner will think, and in the acute phase, genuine physical pain, leads a meaningful proportion of men to withdraw from sexual activity altogether, sometimes well beyond what the physical severity of the condition alone would explain. This avoidance can itself become a secondary contributor to erectile difficulty through simple deconditioning and performance anxiety, compounding the original physical problem. Addressing this psychological dimension directly, alongside physical treatment, is a legitimate and often necessary part of full recovery rather than a separate, optional concern.

No — collagenase injections are approved and used based on curvature severity and disease phase, not on whether erectile dysfunction is also present. In fact, since collagenase specifically targets the plaque tissue believed to contribute to mechanical and venous-leak-related ED, addressing the curvature through injection therapy may indirectly improve the ED component for some men, even though the treatment isn't specifically approved or studied as an ED therapy on its own. A urologist would still evaluate both conditions together when building the overall treatment plan.

Somewhat, but not reliably enough to count on it. Pain typically resolves as the acute phase transitions to the stable phase, and some men do see modest functional improvement once active plaque formation stops, but curvature itself rarely fully resolves without treatment, and any venous-leak component from established scar tissue tends to persist into the chronic phase rather than reversing spontaneously. This is why medical evaluation during the acute phase matters — waiting to see if things improve on their own risks missing the treatment window when interventions are most effective.

Yes — age alone is not a disqualifying factor for penile implant surgery, and it remains one of the most effective and durable options for men with combined severe curvature and significant erectile dysfunction, regardless of whether they're in their 50s, 60s, or beyond. Candidacy depends more on overall surgical fitness and realistic expectations than age specifically. For men who have exhausted less invasive options and have functionally significant combined Peyronie's disease and ED, an implant consultation with a urologist experienced in this specific procedure is a reasonable step at any age within general surgical candidacy.